<DOC>
	<DOCNO>NCT00867672</DOCNO>
	<brief_summary>AML older patient constitute major unmet clinical need since large majority find eligible induction chemotherapy . Reasons decision include host factor ( comorbidities , reduce performance status , functional limitation due age ) , lead often poor tolerance repeat chemotherapy course unfavorable biology underlie disease old patient . Low dose Decitabine show promising efficacy high-risk MDS therefore promising approach also old AML patient . Preliminary result several centre demonstrate excellent feasibility good efficacy treatment . Therefore investigator intend investigate effect two drug add onto low-dose Decitabine show promising synergistic effect vitro preliminary result indicate combination low-dose Decitabine feasible .</brief_summary>
	<brief_title>Study Decitabine Alone Combination With Valproic Acid All-trans Retinoic Acid Acute Myeloid Leukemia</brief_title>
	<detailed_description>By employ 2x2 factorial design , phase II study address possible add efficacy addition one even agents low-dose Decitabine . The primary endpoint study objective response rate ( complete partial remission ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Written inform consent obtain accord international guideline local law ; 2 . Male female patient age &gt; 60 year without upper age limit ; 3 . Patients primary secondary AML accord WHO ( ≥ 20 % blast peripheral blood ( pB ) bone marrow ( BM ) ) expect benefit standard remissioninduction chemotherapy ; 4 . Patients &lt; 30 000 leukocytes/μl ; 5 . Performance status ECOG 0 , 1 , 2 ; 6 . Creatinine &lt; 2.0 mg/dl ( unless leukemiarelated ) ; 7 . Ability understand nature study study relate procedure comply . 1 . AML FAB subtype M3 ; 2 . Previous remissioninduction chemotherapy MDS AML , previous allografting ; 3 . Previous treatment DAC , 5azacytidine , VPA another HDAC inhibitor , ATRA ; 4 . `` Lowdose '' chemotherapy ( e.g . hydroxyurea , cytosine arabinoside ( AraC ) , melphalan , clofarabine etc . ) within 4 week prior DAC treatment , except cytoreduction leukocytosis ≥ 30 000/μl hydroxyurea AraC proscribe study protocol ( section 7.3 7.4 ) ; patient must recover clinically relevant reversible nonhematologic toxicity ; 5 . Treatment tyrosine kinase inhibitor , immunomodulating agent ( IMIDS ) investigational AML treatment within last 4 week time period drug halflife x 5 ( whatever shorter ) first administration DAC ; 6 . Treatment cytokine within previous 4 week ; 7 . Concomitant therapy consider relevant evaluation efficacy safety trial drug ( i.e . chemo immunotherapy ) ; 8 . Other malignancy require treatment ( previous chemotherapy malignancy exclusion criterion ) ; 9 . Cardiac insufficiency NYHA IV ; 10 . Insufficient hepatic function ( bilirubin , AST ALT &gt; = 2.5 x Upper Limit Normal ( ULN ) ) ( unless leukemiarelated ) ; 11 . Fatal hepatic function disorder treatment valproic acid sibling ; 12 . Hepatic porphyria ; 13 . Manifest serious pancreatic function disorder ; 14 . Plasmatic coagulation disorder relate AML ; 15 . Known active hepatitis B C ; 16 . Known HIV infection ; 17 . Other uncontrolled active infection ; 18 . Known allergy soy bean peanuts ; 19 . Psychiatric disorder interferes treatment ; 20 . Patient without legal capacity unable understand nature , significance consequence study ; 21 . Known hypersensitivity , intolerance , one trial drug , another retinoid excipients trial drug ; 22 . Concomitant use investigational drug participation clinical trial within last thirty day start study ; simultaneous participation registry diagnostic trial allow ; 23 . Female patient pregnant breast feeding ; 24 . Fertile patient refuse use safe contraceptive method study ( detail see clinical trial protocol section 5.3 ) ; 25 . Known persistent abuse medication , drug alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Low-dose Decitabine</keyword>
	<keyword>Valproic acid</keyword>
	<keyword>All-trans retinoic acid</keyword>
	<keyword>Older Patients</keyword>
</DOC>